Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F23%3A10001136" target="_blank" >RIV/00064190:_____/23:10001136 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/23:10466332
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/10.1111/all.15817" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1111/all.15817</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/all.15817" target="_blank" >10.1111/all.15817</a>
Alternative languages
Result language
angličtina
Original language name
Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper
Original language description
Introduction: In allergic asthma patients, one of the more common phenotypes might benefit from allergen immunotherapy (AIT) as add-on intervention to pharmacological treatment. AIT is a treatment with disease-modifying modalities, the evidence for efficacy is based on controlled clinical trials following standardized endpoint measures. However, so far there is a lack of a consensus for asthma endpoints in AIT trials. The aim of a task force (TF) of the European Academy of Allergy and Clinical Immunology (EAACI) is evaluating several outcome measures for AIT in allergic asthma. Methods: The following domains of outcome measures in asthmatic patients have been evaluated for this position paper (PP): (i) exacerbation rate, (ii) lung function, (iii) ICS withdrawal, (iv) symptoms and rescue medication use, (v) questionnaires (PROMS), (vi) bronchial/nasal provocation, (vii) allergen exposure chambers (AEC) and (viii) biomarkers. Results: Exacerbation rate can be used as a reliable objective primary outcome; however, there is limited evidence due to different definitions of exacerbation. The time after ICS withdrawal to first exacerbation is considered a primary outcome measure. Besides, the advantages and disadvantages and clinical implications of further domains of asthma endpoints in AIT trials are elaborated in this PP. Conclusion: This EAACI-PP aims to highlight important aspects of current asthma measures by critically evaluating their applicability for controlled trials of AIT. (C) 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30225 - Allergy
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ALLERGY
ISSN
0105-4538
e-ISSN
1398-9995
Volume of the periodical
78
Issue of the periodical within the volume
11
Country of publishing house
US - UNITED STATES
Number of pages
16
Pages from-to
2835-2850
UT code for WoS article
001030585500001
EID of the result in the Scopus database
2-s2.0-85165266586